Pulmonx (LUNG) IPO Opens 111% Higher

Today's IPO for Pulmonx Corporation (NASDAQ: LUNG) opened for trading at $40 after pricing 10,000,000 shares at $19.

BofA Securities and Morgan Stanley are acting as joint lead book-running managers for the offering, and Stifel, Wells Fargo Securities and Canaccord Genuity are acting as lead managers for the offering.

Pulmonx Corporation is a commercial-stage medical device company that provides minimally invasive treatment for patients with severe emphysema, a form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available in more than 25 countries, with over 76,000 valves used to treat more than 19,000 patients.

You May Also Be Interested In

• ITG, Inc. raises $323.4M in Nasdaq IPO at $16 per share
• ITG prices IPO at $16 per share on Nasdaq
• Clarivate Analytics (CCC) Reiterated at Buy by Stifel: 'Should be Standing as a Winner'